Loading clinical trials...

Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers | Clinical Trials | Clareo Health

RECRUITINGNA

Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers

Evaluation of a Communication Intervention (Hematolo-GIST) for Large B-Cell Lymphoma Providers

NCT05940272•Memorial Sloan Kettering Cancer Center

Summary

The purpose of this study is to develop and test a new communication training intervention called Hematolo-GIST to help oncologists communicate with patients about their lymphoma diagnosis and advance care planning.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Providers
•Currently a an MSK provider caring for patients with DLBCL (including DLBCL-transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL) which are histologically similar and treated as large-cell lymphoma)
•Patients
•Per medical record, is currently being treated by a provider who is participating in this study (for the purposes of this study, "treating provider" will be defined as any provider who provides care related to the patient's lymphoma diagnosis)
•Per medical record, has a diagnosis of DLBCL including DLBCL-transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL) which are histologically similar and clinically treated as large-cell lymphoma
•Per medical record, relapse/ refractory disease within 12 months of 4 cycles of first line therapy OR relapse after 2 cycles of later line therapy or or autologous stem cell transplant (ASCT)
•Self-identify as Black and/or White
•Per medical record, 18 years of age or older
•Per self-report, fluent in English\*\*
•* Language verification: Prior to enrollment, patients will be asked the following two questions by a Clinical Research Coordinator (CRC) to verify English fluency necessary for participation in the study:
+2 more criteria

Exclusion Criteria

•Providers
•Per self-report, planning to leave the cancer center in the next 12 months
•Patients
•Cognitively impaired as demonstrated by (Blessed Orientation- Memory- Concentration (BOMC) score of ≥ 11
•Per research staff judgment and/or self-report, too ill or weak to complete study procedures
•Per medical record or self-report, receiving hospice care at the time of enrollment

Locations (2)

Memorial Sloan Kettering Cancer Center (All protocol activities)

New York, New York, United States

NEW YORK PRESBYTERIAN HOSPITAL (Data Collection Only)

New York, New York, United States

Key Dates

Start Date

July 3, 2023

Primary Completion Date

July 3, 2028

Completion Date

July 3, 2028

Last Updated

October 9, 2025

Enrollment

ESTIMATED participants

Conditions

Lymphoma, B-CellLymphomaLarge-cell LymphomaLarge B-cell LymphomaDLBCL - Diffuse Large B Cell LymphomaMediastinal B-Cell Diffuse Large Cell Lymphoma

Interventions

Hematolo-GIST Training

BEHAVIORAL

Participants Appointment

BEHAVIORAL

Contacts

Kelly McConnell, PhD

CONTACT

646-888-0026 McConneK@mskcc.org

Revecca Saracino, PhD

CONTACT

646-888-0263 jamesr@mskcc.org

Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

NCT07388563

Lymphoma, T Cell, PeripheralT-cell Lymphoma+4 more

View study

RECRUITINGPHASE3

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

NCT06337318

Classic Follicular LymphomaFollicular Lymphoma With Unusual Cytological Features

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 9, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers

Inclusion Criteria

Exclusion Criteria

Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients

U69-CART-Cells For R/R T-ALL